Panita Mettikanont1, Chalermrat Bunchorntavakul2, K Rajender Reddy3. 1. Faculty of Medicine, Thammasat University, Bangkok, Thailand. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. 3. Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Hepatitis C virus (HCV) genotype 6 (GT6) is predominantly encountered in Southeast Asia and data on GT6 response to direct-acting antiviral (DAA) therapy are relatively limited. AIM: To review the epidemiology and virologic outcome of DAA regimens in HCV GT6 patients. METHODS: Electronic literature search of PubMed, EMBASE, and The Cochrane Library databases were conducted. RESULTS: Hepatitis C virus genotype 6 is the most genetically diverse, has a prevalence of 19.9%-95.6% in HCV infected patients in Southeast Asia and has been associated with a higher risk of HCC in those with cirrhosis. After an extensive literature review, a total of 20 studies were selected to assess study population and treatment outcomes (total of 938 GT6 patients were included); 12 were clinical trials and eight were observational studies. Sustained virologic response at week 12 (SVR 12) following glecaprevir/pibrentasvir (n = 4; 108 patients), ledipasvir/sofosbuvir (n = 8; 427 patients), sofosbuvir/velpatasvir with or without voxilaprevir (n = 5; 171 patients), sofosbuvir/daclatasvir (n = 3; 172 patients) and sofosbuvir with ribavirin (n = 3; 60 patients) was 98%-100%, 64%-100%, 100%, 88%-94% and 100%, respectively. Failure was mostly in those with cirrhosis and prior treatment experience. DAA therapy was well tolerated and with a serious adverse event rate of <5%. CONCLUSIONS: Hepatitis C virus genotype 6 is genetically diverse and is highly prevalent in Asia. While SVR rates have been high, cirrhosis and prior treatment experience marginally compromise response to DAAs. Large scale and exclusive studies in HCV genotype 6 prevalent areas are needed, while the current evidence suggests that DAAs are highly effective and safe.
BACKGROUND:Hepatitis C virus (HCV) genotype 6 (GT6) is predominantly encountered in Southeast Asia and data on GT6 response to direct-acting antiviral (DAA) therapy are relatively limited. AIM: To review the epidemiology and virologic outcome of DAA regimens in HCV GT6 patients. METHODS: Electronic literature search of PubMed, EMBASE, and The Cochrane Library databases were conducted. RESULTS:Hepatitis C virus genotype 6 is the most genetically diverse, has a prevalence of 19.9%-95.6% in HCV infectedpatients in Southeast Asia and has been associated with a higher risk of HCC in those with cirrhosis. After an extensive literature review, a total of 20 studies were selected to assess study population and treatment outcomes (total of 938 GT6 patients were included); 12 were clinical trials and eight were observational studies. Sustained virologic response at week 12 (SVR 12) following glecaprevir/pibrentasvir (n = 4; 108 patients), ledipasvir/sofosbuvir (n = 8; 427 patients), sofosbuvir/velpatasvir with or without voxilaprevir (n = 5; 171 patients), sofosbuvir/daclatasvir (n = 3; 172 patients) and sofosbuvir with ribavirin (n = 3; 60 patients) was 98%-100%, 64%-100%, 100%, 88%-94% and 100%, respectively. Failure was mostly in those with cirrhosis and prior treatment experience. DAA therapy was well tolerated and with a serious adverse event rate of <5%. CONCLUSIONS:Hepatitis C virus genotype 6 is genetically diverse and is highly prevalent in Asia. While SVR rates have been high, cirrhosis and prior treatment experience marginally compromise response to DAAs. Large scale and exclusive studies in HCV genotype 6 prevalent areas are needed, while the current evidence suggests that DAAs are highly effective and safe.
Authors: Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal Journal: World J Gastroenterol Date: 2019-08-07 Impact factor: 5.742
Authors: Betty B Yao; Linda M Fredrick; Gretja Schnell; Kris V Kowdley; Paul Y Kwo; Fred Poordad; Kinh Nguyen; Samuel S Lee; Christophe George; Florence Wong; Edward Gane; Armand Abergel; Catherine W Spearman; Tuan Nguyen; Manh Hung Le; Thuy Tt Pham; Federico Mensa; Tarik Asselah Journal: Liver Int Date: 2020-06-11 Impact factor: 5.828
Authors: Barnaby Flower; Leanne McCabe; Chau Le Ngoc; Hung Le Manh; Phuong Le Thanh; Thuan Dang Trong; Thu Vo Thi; Hang Vu Thi Kim; Thanh Nguyen Tat; Dao Phan Thi Hong; An Nguyen Thi Chau; Tan Dinh Thi; Nga Tran Thi Tuyet; Joel Tarning; Cherry Kingsley; Evelyne Kestelyn; Sarah L Pett; Guy Thwaites; Vinh Chau Nguyen Van; David Smith; Eleanor Barnes; M Azim Ansari; Hugo Turner; Motiur Rahman; Ann Sarah Walker; Jeremy Day; Graham S Cooke Journal: Open Forum Infect Dis Date: 2021-06-09 Impact factor: 3.835